2015 Annual Report – DTR 6.3.5 Disclosure

2015 Annual Report – DTR 6.3.5 Disclosure

March 29, 2016

March 29, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that the following documents have today been posted or otherwise made available to shareholders:

> 2015 Annual Report
> Notice of the 2016 Annual General Meeting
> Form of Proxy

In accordance with Listing Rule 9.6.1R, a copy of each of these documents has been uploaded to the National Storage Mechanism and will be available for viewing shortly.

The 2015 Annual Report and Notice of the 2016 Annual General Meeting are also available on Shire’s website: www.shire.com

Disclosure & Transparency Rule (“DTR”) 6.3.5R requires the Company to disclose to the media certain information from its Annual Report if that information is of a type that would be required to be disseminated in a half-yearly report. The information contained in the Appendix to this announcement, together with the Company’s unaudited full year results for the year ended December 31, 2015, issued on February 11, 2016, constitute the materials required by DTR 6.3.5R to be communicated to the media in unedited full text through a Regulatory Information Service. This material is not a substitute for reading the full 2015 Annual Report.

The information included in the Appendix is extracted from the 2015 Annual Report which was approved by the Board of Directors on February 23, 2016. Defined terms used in the Appendix refer to terms as defined in the 2015 Annual Report, unless the context otherwise requires.

Oliver Strawbridge
Senior Assistant Company Secretary

Download the PDF for the full release 

For further information please contact:

Investor Relations

Sarah Elton-Farr[email protected]+44 1256 894157


Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.